Leslie Lee | AMiner学者主页

全面呈现 [Leslie Lee] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（82）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Supplementary Table 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

qPCR primer sequences for Apopanel of BCL2 family members

2023

引用

AI阅读

2Supplementary Table 4 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

Laurent Salphati,Timothy P. Heffron,Bruno Alicke,Merry Nishimura,Kai Barck,Richard A. Carano,Jonathan Cheong,Kyle A. Edgar,Joan Greve,Samir Kharbanda,Hartmut Koeppen,Shari Lau,

PDF file - 47K, Anti-proliferative EC50's for GNE-317 against a Panel of Nine Glioma Cell lines

2023

引用

AI阅读

3Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

Correlation of mRNA expression of BCL2 family members and sensitivity to venetoclax or navitoclax in HMCLs

2023

引用

AI阅读

4Supplementary Figure 1 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death in Vitro and in Vivo

Jeffrey J. Wallin,Jane Guan, Wei,Leslie B. Lee,Leanne Berry,Lisa D. Belmont,Hartmut Koeppen,Marcia Belvin,Lori S. Friedman,Deepak Sampath

PDF file, 89KB, FACS Analysis of HER2 Expression in MCF7-neo/HER2 Breast Cancer Cell Line.

2023

引用

AI阅读

5Supplementary Table 1 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

Laurent Salphati,Timothy P. Heffron,Bruno Alicke,Merry Nishimura,Kai Barck,Richard A. Carano,Jonathan Cheong,Kyle A. Edgar,Joan Greve,Samir Kharbanda,Hartmut Koeppen,Shari Lau,

PDF file - 58K, Bioluminescence Analysis of U87 Intracranial Tumors in Mice at the Start of Treatment (Day 7 post-surgery) and at the End of Study (Day 28)

2023

引用

AI阅读

6Supplementary Figure and Table Legends from Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

Kyle A. Edgar,Jeffrey J. Wallin,Megan Berry,Leslie B. Lee, Wei,Deepak Sampath,Lori S. Friedman,Marcia Belvin

Supplementary Figure and Table Legends from Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

2023

引用

AI阅读

7Supplementary Figure 2 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death in Vitro and in Vivo

Jeffrey J. Wallin,Jane Guan, Wei,Leslie B. Lee,Leanne Berry,Lisa D. Belmont,Hartmut Koeppen,Marcia Belvin,Lori S. Friedman,Deepak Sampath

PDF file, 137KB, Time-Lapse Photomicrographs of HCC-1954 Breast Cancer Cells Treated with GDC-0941, Docetaxel (DTX) or the Combination of Both Drugs.

2023

引用

AI阅读

8Supplementary Figures 1 - 5 from Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That is Efficacious in Multiple Tumor Models

Jie Lin,Deepak Sampath,Michelle A. Nannini,Brian B. Lee,Michael Degtyarev,Jason Oeh,Heidi Savage,Zhengyu Guan,Rebecca Hong,Robert Kassees,Leslie B. Lee,Tyler Risom,

PDF file - 954K, Supplemental Figures: Figure S1. Chemical structure of the Akt inhibitor GDC-0068. Figure S2. Effect of GDC-0068 on cell cycle and apoptotic response on PC-3 and MCF7-neo/HER2 cell lines. Figure S3. Western blot analysis of indicated proteins in isogenic MCF10A cells with and without PTEN knockout in the presence of 20 or 0.2 ng/ml EGF. Figure S4. Representative immunohistochemistry staining images of cleaved caspase-3 in TOV-21G.x1 tumors. Figure S5. Combination effects between GDC-0068 and chemotherapeutic agents in vitro.

2023

引用

AI阅读

9Supplementary Table 2 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

Laurent Salphati,Timothy P. Heffron,Bruno Alicke,Merry Nishimura,Kai Barck,Richard A. Carano,Jonathan Cheong,Kyle A. Edgar,Joan Greve,Samir Kharbanda,Hartmut Koeppen,Shari Lau,

PDF file - 60K, Plasma Concentrations, Brain Concentrations and Brain-to-Plasma Ratio Measured at the End of Study (42 days) 2 hours Following the Last Daily PO Administration of GNE-317 (40 mg/kg), GDC-0941 (250 mg/kg) or GDC-0980 (10 mg/kg) to GS2 Tumor-Bearing Mice

2023

引用

AI阅读

10Supplementary Figure 2 from Bcl-2/Bcl-x<sub>L</sub> Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan,Maureen Wong,Michelle Nannini,Rebecca Hong,Leslie B. Lee, S. D. Price,Karen Williams,Pierre Pascal Savy,Yue Peng,Deepak Sampath,Jeffrey Settleman,Wayne J. Fairbrother,

PDF file - 558K, Biochemical Selectivity of G-963. Percent inhibition of various kinases treated with 1uM G-963. Assays were performed at Invitrogen using their SelectScreenR Kinase profiling service

2023

引用

AI阅读

11Supplementary Figure 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

Immunoblots of BCL-2, BCL-XL and MCL-1 in HMCL tumor xenografts

2023

引用

AI阅读

12Supplementary Table 3 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

BCL2, BCL2L1 and MCL1 mRNA in CD138 primary MM patient samples and sensitivity to veneteclax ex vivo

2023

引用

AI阅读

13Supplementary Figure 3 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death in Vitro and in Vivo

Jeffrey J. Wallin,Jane Guan, Wei,Leslie B. Lee,Leanne Berry,Lisa D. Belmont,Hartmut Koeppen,Marcia Belvin,Lori S. Friedman,Deepak Sampath

PDF file, 125KB, Biomarkers for Cell Cycle Progression of HCC-1954 Cells After Synchronization Release.

2023

引用

AI阅读

14Supplementary Figure 4 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

Conceptual workflow for establishing BCL-2 family IHC cut-offs for analysis of MM patient tumor samples

2023

引用

AI阅读

15Supplementary Table 1 from Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan,Maureen Wong,Michelle A. Nannini,Rebecca Hong,Leslie B. Lee,Stephen Price,Karen Williams,Pierre Pascal Savy,Peng Yue,Deepak Sampath,Jeffrey Settleman,Wayne J. Fairbrother,

PDF file - 39K, Summary of Combination Matrices for Navitoclax and G-963 in Pancreatic Cancer Cell Lines. The data reflect the average of three independent runs performed in quadruplicate

2023

引用

AI阅读

16Supplementary Tables 1 - 3 from Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That is Efficacious in Multiple Tumor Models

Jie Lin,Deepak Sampath,Michelle A. Nannini,Brian B. Lee,Michael Degtyarev,Jason Oeh,Heidi Savage,Zhengyu Guan,Rebecca Hong,Robert Kassees,Leslie B. Lee,Tyler Risom,

XLSX file - 74K, Table S1. Enzymatic potency, selectivity and cellular potency of GDC-0068 Table S2. GDC-0068 IC50 profile on cell viability and genetic background of cancer cell lines Table S3. Maximum percent body weight changes of mice treated with GDC-0068 single agent and in combination with chemotherapeutic agents

2023

引用

AI阅读

17Supplementary Figure 4 from GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death in Vitro and in Vivo

Jeffrey J. Wallin,Jane Guan, Wei,Leslie B. Lee,Leanne Berry,Lisa D. Belmont,Hartmut Koeppen,Marcia Belvin,Lori S. Friedman,Deepak Sampath

PDF file, 148KB, Cell Cycle Analysis of MCF7-neo/HER2 Cells After Treatment with GDC-0941, Docetaxel (DTX) or the Combination of Both Drugs.

2023

引用

AI阅读

18Supplementary Table 3 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier

Laurent Salphati,Timothy P. Heffron,Bruno Alicke,Merry Nishimura,Kai Barck,Richard A. Carano,Jonathan Cheong,Kyle A. Edgar,Joan Greve,Samir Kharbanda,Hartmut Koeppen,Shari Lau,

PDF file - 57K, Selectivity of GNE-317 against a Panel of 59 Kinases. GNE-317 was Tested at 1 M in the Invitrogen SelectScreen

2023

引用

AI阅读

19Legends for Tables S1 to S3 and Figures S1 to S5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

Legends for Tables S1 to S3 and Figures S1 to S5

2023

引用

AI阅读

20Supplementary Figure 5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose,Joel D. Leverson,Franklin Peale,Erwin R. Boghaert,Lisa D. Belmont,Nguyen Tan,Amy Young,Michael Mitten,Ellen Ingalla,Walter C. Darbonne,Anatol Oleksijew,Paul Tapang,

BCL-2 and BCL-XL IHC correlates with qPCR and immunobot analysis of HMCLs

2023

引用

AI阅读

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

Deepak Sampath合作论文数Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston43

Jeffrey John Wallin合作论文数32

Salphati Laurent合作论文数29

Jodie Pang合作论文数28

Belmont Lisa合作论文数26

Lori Friedman合作论文数NextRNA Therapeutics;ORIC Pharmaceuticals, Inc25

Hartmut Koeppen合作论文数19

Plise Emile G合作论文数18

Jason Oeh合作论文数18

Peng Yue合作论文数ReviR Therapeutics18

Nguyen Van Tan合作论文数18

Xiaolin Zhang合作论文数17

Jim Nonomiya合作论文数16

Stephen Gould合作论文数16

Michelle Nannini合作论文数14

Cristina Lewis合作论文数14

Cheong Jonathan合作论文数12

steve price合作论文数11

Heidi S Phillips合作论文数Department of Bioinformatics and Computational Biology, Genentech Inc11

Merry Nishimura合作论文数11

Daniel P. Sutherlin合作论文数10

Souers Andrew J合作论文数10

Erwin R. Boghaert合作论文数10

Joel Leverson合作论文数Treeline Biosciences10

Franklin Peale合作论文数Genentech10

Steve Sideris合作论文数10

Walter C. Darbonne合作论文数Karmanos Cancer Institute;De - troit;Johns Hopkins University10

Wayne J Fairbrother合作论文数Department of Protein Engineering;Genentech , Inc .;Department of Protein Engineering, Genentech , Inc .10

Richard Goldsmith合作论文数9

Michael Mitten合作论文数9

Punnoose Elizabeth A合作论文数9

Oleksijew Anatol合作论文数9

Maiga Sophie合作论文数9

Ellen Ingalla合作论文数Calico Life Sciences9

Amy E. Young合作论文数Department of Obstetrics and Gynecology, Baylor College of Medicine9

Richard Carano合作论文数Genentech9

Chudi Ndubaku合作论文数9

Lesley J. Murray合作论文数9

Paul Tapang合作论文数9

Joan M. Greve合作论文数School of Medicine, Stanford University9

相似学者

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn